Septerna (NASDAQ:SEPN - Get Free Report) will likely be releasing its Q1 2025 earnings data on Thursday, June 26th. Analysts expect Septerna to post earnings of ($0.38) per share for the quarter.
Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Septerna Trading Up 2.4%
Shares of SEPN opened at $10.49 on Thursday. The stock has a fifty day moving average price of $8.27 and a two-hundred day moving average price of $12.10. Septerna has a 52-week low of $4.17 and a 52-week high of $28.99.
Analysts Set New Price Targets
Several brokerages have issued reports on SEPN. Cantor Fitzgerald lifted their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Wells Fargo & Company lifted their price objective on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th.
Check Out Our Latest Stock Report on Septerna
Institutional Investors Weigh In On Septerna
A hedge fund recently raised its stake in Septerna stock. Woodline Partners LP lifted its position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) by 94.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 582,585 shares of the company's stock after acquiring an additional 282,585 shares during the quarter. Woodline Partners LP owned approximately 1.31% of Septerna worth $3,373,000 at the end of the most recent reporting period.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
